GWPH - GW Pharmaceuticals plc

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

GW Pharmaceuticals plc

Sovereign House
Vision Park Chivers Way Histon
Cambridge CB24 9BZ
United Kingdom
44 1223 266 800
http://www.gwpharm.com

SectorHealthcare
IndustryDrug Manufacturers - Major
Full Time Employees791

Key Executives

NameTitlePayExercisedYear Born
Dr. Geoffrey W. Guy BSc, LMSSA, Dip Pharm Med, MB BS, MRCS Eng, LRCPFounder & Chairman512.33k2.14M1954
Mr. Justin D. GoverCEO & Exec. Director565.98k1.61M1971
Mr. Scott M. GiacobelloChief Financial Officer377.05k104.07k1970
Mr. Douglas B. SnyderChief Legal Officer506.96k103.96k1964
Dr. Volker Knappertz M.D., D.Sc.Chief Medical Officer490.44k155.46k1965
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. Its lead product is Epidiolex, an oral medicine for the treatment of refractory childhood epilepsies, as well as for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis complex, and infantile spasms. The company also develops and markets Sativex, an oromucosal spray for the treatment of spasticity due to multiple sclerosis. In addition, it develops various product candidates for the treatment of glioblastoma, neonatal hypoxic-ischemic encephalopathy, and schizophrenia. Further, the company has license and development agreements with Almirall S.A.; Bayer HealthCare AG; Ipsen Biopharm Ltd; and Neopharm Group. It primarily operates in Europe, the United Kingdom, the United States, Canada, and Asia. GW Pharmaceuticals plc was founded in 1998 and is based in Cambridge, the United Kingdom.

Corporate Governance

GW Pharmaceuticals plc’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.